We are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's...
Earnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented...
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
In the HSGX longs community (i.e. Stocktwits) it is expected that there will be another update by the company CEO Adam Grizley by the end of year. As there haven't been any updates on the FDA discussions concerning BLA submission since 11-29-2018. The product NeoCart failed phase 3 because it didn't meet Histogenics criteria, not the FDA's. While the FDA continue...
Could this go back to $22? with news of FDA clearance...Maybe
EDAP has recieved FDA clearance on its prostate device. With a price target of $6 this has room to run. Shorts could get trapped. A mourning dip got caused some panic but it appears to be holding the $3.70 range and looking to setup for another break out after the rsi cools down a bit.
$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes. Item 1.01 Entry into a Material Definitive Agreement Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative...
DD below in link
$CELZ DD As It Stands, this is now one of my Long Term plays that I have added to my portfolio: I like what I see here and am glad to have the shares I have. Targeting BILLIONS IN REVENUE FOLKS AND THE TECHNOLOGY IS REAL AND PROVEN. AMAZING!!! WORTHY OF A MARKET CAP 50-100 MILLION TODAY THATS A PPS .104 - .208! Fellow investors it looks to me like...
There has been a long quiet period after the last move up to $1 area. From this sub .10 range, I think we can see another big run as pending news on test results is expected near term.
Reposting as it didn't post properly the first time $DCTH Highlights for the first quarter of 2017 and the recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter. CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT...
1. Won their Injunction 2. PreClinical Trials for its Immunotronics Platform 3. Filed for Orphan Drug Status 4. Over 20 patents 5. Form 4s filed by insiders 6. Converts being bought by Company and Institutions 7. Uplistment 8. President and CEO has been filing form 4's everyday so far the past couple weeks
$USRM is currently awaiting RMAT designation which approved (And there is a 90% or higher chance it will) gives it similar qualities as Breakthrough Therapy, Accelerated Approval, and Priority Review. Basically, they can provisionally approve the drug or device for marketing and then provided the drug or device proves safe and reasonably effective, they will gain...
$PTLF PetLife recent news indicates 1st step towards #FDA meeting and subsequent submission has been completed. 2 more studies coming up. Stock has come down and stabilized over the past month. Looks ready to head back up here. On watch for next study results.
Upcoming FDA decision and Fib retracement